SAN FRANCISCO (KGO) -- With the world racing to develop a vaccine for COVID-19, there's an ethical debate about a strategy that could potentially speed up the testing.
That strategy is a form of clinical trial that involves deliberately exposing volunteers to the virus.
BUILDING A BETTER BAY AREA: The Race for a Vaccine
Right now, roughly half a dozen government-backed COVID-19 vaccine candidates are lined up in traditional clinical trials across the U.S.
Thousands of volunteers will ultimately receive doses of a specific candidate, then return to their normal lives where researchers will follow them for signs of infection or immunity. But what if researchers didn't have to wait for those volunteers to come in contact with the virus naturally, and instead, exposed them to it deliberately? A technique known as a "human challenge trial."
"These things are not done very often, they're certainly not done in the modern era. They were done in years past," says Dr. Yvonne Maldonado, M.D., an infectious disease specialist at Stanford Health Care.
Dr. Maldonado points to smallpox as an early example. An English doctor successfully tested his own rudimentary vaccine on an eight-year-old boy. Before modern clinical trials evolved, human challenge trials offered a relatively simple and fast way to get data back on a vaccine, but with dangers included.
"Of course the risk of a healthy young person is not zero no matter what. So you could still risk somebody getting very sick," says Dr. Maldonado.
With a disease there is still no approved treatment for.
But on Friday, Dr. Anthony Fauci confirmed to several media sources that the U.S. is now working on a weakened version of the COVID virus, which would be needed for any human challenge trial. Dr. Fauci said the move was only precautionary and that no trials are currently planned.
Still, at a recent web briefing by UCSF, Dr. Joel Ernst, M.D. said leaders in the medical community have been actively debating the pros and cons.
"So there are disagreements about how much risk volunteers or participants would be subjected to," explained Dr. Ernst.
At least one vaccine group at Oxford has already requested permission from the U.K. to conduct a challenge trial if the numbers of available volunteers were to drop. Some advocates argue that tests with a weakened virus could be conducted quickly and safely. Still, with millions of doses required world-wide, the stakes may be historically high.
"If we don't produce a safe vaccine we will lose the confidence of the public immediately, and it's really hard to regain that," Dr. Maldonado points out.
With the no shortage of COVID-19 patients at this point, Dr. Fauci said he still believes the current trial structure will prove the quickest path to a safe vaccine.
Take a look at all of ABC7's Building a Better Bay Area stories and videos here.
If you have a question or comment about the coronavirus pandemic, submit yours via the form below or here.
Get the latest news, information and videos about the novel coronavirus pandemic here
RELATED STORIES & VIDEOS:
- COVID-19 Help: Comprehensive list of resources, information
- Watch list: Counties where COVID-19 is getting worse
- MAP: Everything that's open, forced to close in Bay Area
- Everything to know about CA's confusing reopening plan, summer shutdown and what comes next
- From salons to dinner parties: Experts rate the risk of 12 activities
- Coronavirus origin: Where did COVID-19 come from?
- Life after COVID-19: Here's what restaurants, gyms will look like
- What is a COVID-19 genetic, antigen and antibody test?
- What will it take to get a COVID-19 vaccine and how will it be made?
- What does COVID-19 do to your body and why does it spread so easily?
- Here's how shelter in place, stay at home orders can slow spread of COVID-19
- Coronavirus Timeline: Tracking major moments of COVID-19 pandemic in San Francisco Bay Area
- Experts compare face shield vs. face mask effectiveness
- COVID-19 Diaries: Personal stories of Bay Area residents during novel coronavirus pandemic
- Coronavirus Doctor's Note: Dr. Alok Patel gives his insight into COVID-19 pandemic